Cargando…

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China

BACKGROUND: Few data exist on the immunogenicity and safety of an inactivated enterovirus 71 vaccine (EV71 vaccine) coadministered with trivalent split-virion inactivated influenza vaccine (IIV3) in infants. METHODS: This trial was a phase 4, randomized, controlled trial. Infants aged 6-11 months we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yaping, Xiao, Yanhui, Ye, Ying, Jiang, Feng, He, Hanqing, Luo, Linyun, Chen, Haiping, Shi, Lubin, Mu, Qiuyue, Chen, Wei, Guo, Xue, Zhang, Min, Li, Jun, Guan, Qinghu, Chen, Zhiping, Yang, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772018/ https://www.ncbi.nlm.nih.gov/pubmed/36569946 http://dx.doi.org/10.3389/fimmu.2022.1080408

Ejemplares similares

Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6–7 Months: A Phase 4, Randomized, Controlled Trial
por: Xiao, Yanhui, et al.
Publicado: (2023)

Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques
por: Liu, Chia-Chyi, et al.
Publicado: (2014)

Inactivated enterovirus A71 vaccines and moving forward
por: Shimizu, Hiroyuki
Publicado: (2021)

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial
por: Chen, Haiping, et al.
Publicado: (2022)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China
por: Jiang, Hongchao, et al.
Publicado: (2021)

Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China
por: Ye, Lixia, et al.
Publicado: (2021)

Transplantation of Enterovirus 71 Virion Protein Particle Vaccine Protects Against Enterovirus 71 Infection in a Neonatal Mouse Model
por: Lei, Li, et al.
Publicado: (2021)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production
por: Herrera-Rodriguez, José, et al.
Publicado: (2019)

Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice
por: Chang, Junliang, et al.
Publicado: (2015)

A Bivalent Inactivated Vaccine Prevents Enterovirus 71 and Coxsackievirus A16 Infections in the Mongolian Gerbil
por: Yi, Eun-Je, et al.
Publicado: (2023)

112 The Development of Enterovirus 71 Vaccine
por: Xiuling, Li, et al.
Publicado: (2014)

Challenges to Licensure of Enterovirus 71 Vaccines
por: Lee, Min-Shi, et al.
Publicado: (2012)

Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations
por: Liu, Longding, et al.
Publicado: (2015)

Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus
por: Zhang, Yuntao, et al.
Publicado: (2022)

Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV Nanoparticles
por: Savard, Christian, et al.
Publicado: (2011)

Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015
por: Asavapiriyanont, Suvanna, et al.
Publicado: (2018)

Exosomes cloak the virion to transmit Enterovirus 71 non-lytically
por: Gu, Jiaqi, et al.
Publicado: (2019)

Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in China
por: Liu, Xiaodong, et al.
Publicado: (2022)

Enterovirus 71 infection and vaccines
por: Yi, Eun-Je, et al.
Publicado: (2017)

Enterovirus A71 Vaccines
por: Li, Mei-Ling, et al.
Publicado: (2021)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

531 Split-virion compared to Subunit Influenza Trivalent Influenza Vaccines Has Greater Effectiveness in Older Adults
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys
por: In, Hyun Ju, et al.
Publicado: (2018)

A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged
por: Kannan, Senthil, et al.
Publicado: (2015)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch
por: Frolov, Vladimir G., et al.
Publicado: (2008)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Enterovirus 71 Virion-Associated Galectin-1 Facilitates Viral Replication and Stability
por: Lee, Pei-Huan, et al.
Publicado: (2015)

Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time
por: Huang, Kuan-Ying A., et al.
Publicado: (2017)

Antivirals and vaccines for Enterovirus A71
por: Lin, Jing-Yi, et al.
Publicado: (2019)

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
por: Tsunetsugu-Yokota, Yasuko
Publicado: (2007)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine
por: Rioux, Gervais, et al.
Publicado: (2014)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kmnk00ouq4ain01i1g36ht8i3s